Evidence map›Paper›PMID 39120791›Full record

ReviewDrug delivery and translational research2025

Unlocking the potential of beta-glucans: a comprehensive review from synthesis to drug delivery carrier potency.

Nivethaa Eluppai Asthagiri Kumaraswamy, Sivasankari Jayaramamurthy, Catherine Ann Martin, Baskar Srinivasan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Drug delivery and translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nivethaa Eluppai Asthagiri KumaraswamyDepartment of Physics, B S Abdur Rahman Crescent Institute of Science and Technology, Vandalur, Chennai, 600048, India. nivethaaeak3@gmail.com.
Sivasankari JayaramamurthyDepartment of Physics, B S Abdur Rahman Crescent Institute of Science and Technology, Vandalur, Chennai, 600048, India.
Catherine Ann MartinDr. Rela Institute and Medical Centre, National Foundation for Liver Research, Chromepet, Chennai, 600044, India.
Baskar SrinivasanDepartment of Physics, Easwari Engineering College, Ramapuram, Chennai, 600089, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Modernization and lifestyle changes have resulted in a number of diseases, including cancer, that require complicated and thorough treatments. One of the most important therapies is the administration of antibiotics and medicines. This is known as chemotherapy for cancer, and it is a regularly utilised treatment plan in which the medications used have negative side effects. This has resulted in extensive research on materials capable of delivering pharmaceuticals to particular targets over an extended period of time. Biopolymers have often been preferred as effective drug delivery carriers. Of these, β-glucan, a natural polysaccharide, has not been extensively studied as a drug delivery carrier, despite its unique properties. This review discusses the sources, extraction techniques, structures, and characteristics of β-glucan to provide an overview. Furthermore, the different methods employed to encapsulate drugs into β-glucan and its role as an efficient drug, SiRNA and Plasmid DNA carrier have been elaborated in this article. The capacity of β-glucan-based to specifically target and alter tumour-associated macrophages, inducing an immune response ultimately resulting in tumour suppression has been elaborated. Finally, this study aims to stimulate further research on β-glucan by thoroughly describing its many characteristics and demonstrating its effectiveness as a drug delivery vehicle.

Indexed as

beta-GlucansDrug CarriersAnimalsAntineoplastic AgentsHumansNeoplasmsAntineoplastic Agentsbeta-GlucansDrug CarriersDrug delivery carrierSourcesStructureTumor associated macrophagesβ-glucan

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.